[Etophylline clofibrate in the treatment of familial combined hyperlipoproteinemia].
The authors investigated the effect of the hypolipaemic agent ethophylline clofibrate (Duolip forte) on some parameters of the lipid and carbohydrate metabolism in patients with combined familial hyperlipoproteinaemia. They administered the pharmaceutic to 12 patients-500 mg for a period of 3 months. As to biochemical parameters they assessed the total cholesterol, triglyceride, HDL-cholesterol, apo-B, apo-A-I; blood glucose and IRI levels using the glucose tolerance test following the dose of 75 g glucose. The patients were checked on and three months after the onset of treatment. During treatment a significant drop of the apo-B level occurred (1.34 +/- 0.12, 1.20 +/- 0.15 g/l, p < 0.05) and of the fasting blood glucose level (5.7 +/- 0.62, 5.0 +/- 0.34 mmol/l, p < 0.005), whereby the blood sugar and IRI levels after the glucose load did not change significantly. The authors did not record a significant effect on the total cholesterol, triglyceride and HDL-cholesterol levels. The results of the investigation indicate that Duolip forte is a pharmaceutic which can exert a favourable effect on the apo-B level and the blood glucose level during combined hypolipaemic and/or antidiabetic treatment.
Raslová
K
K
Oddelenie porúch lipidového a glycidového metabolizmu, Ustav preventívnej a klinickej medicíny, Bratislava.
Hucková
M
M
D001055:Apolipoproteins B / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male
D001055:Apolipoproteins B; D001786:Blood Glucose; D000960:Hypolipidemic Agents; C028764:etofylline clofibrate; D002994:Clofibrate
Etofyllinclofibrat v liecbe familiárnej kombinovanej hyperlipoproteinémie.